


Curriculum  
Vitae  
Europass



Personal  
Informationsi

Surname and  
first name

***Prof. Farinati Fabio***

Address

*Corso Vittorio Emanuele II, 110, 35123, Padova*

Telephon

*Mobile: 338-9346770*

Fax

*049-8760820*

E-mail

[fabio.farinati@unipd.it](mailto:fabio.farinati@unipd.it)

CF

*FRNFBA53M29L736C*

Citizenship

*Italian*

Birth date

*28.08.1953*

Professional  
experience

***1978 - Laurea in Medicine and Surgery at Padua University (110/110 and Laude)***

***1982 - Specialization in Gastroenterology and Digestive Endoscopy (70/70 and Laude) at Padua University.***

***1980 – University Researcher at the Institute of Internal Medicine of Padua University.***

***1983-4 - Assistant Medical Professor at the Sophie Davies School of Biomedical Education, City University in New York, 1983-1984.***

***1985 - Specialization in Oncology at Padua University (68/70)***

***1998 – Tenure as a Researcher at Padua University.***

***2005 – Associate Professor of Gastroenterology***

***2016 – Full Professor of Gastroenterology***

***2017 - Director Gastroenterology, Padua University Hospital***

*Italian, English (fluent), French (basic)*

### **International Experiences**

1. *Educational Commission for Foreign Medical Graduates Award (U.S.A.), 1982.*
2. **Research Fellow of the Alcohol Research and Treatment Center of the Mount Sinai School of Medicine, New York (USA), 1983.**
3. **Assistant Medical Professor at the Sophie Davies School of Biomedical Education at the City University di New York, 1983-1984.**
4. **Visiting Assistant Professor at the City University of New York Medical School, 1985**

### **Professional appointments**

**Unit of High Specialization in GI Oncology, Director, 2007**

**Unit of Hepatology, Director, 2009**

**Unit of Gastroenterology, Director, 2017**

### ***Principal Investigator for international multicenter studies on:***

- *Sorafenib*
- *Cabozantinib*
- *Regorafenib*
- *Brivanib*
- *Everolimus*
- *GC33*

### ***Cohoperative Groups***

*Founding Member of the **ITA.Li.CA (Italian Liver Cancer)**, multicenter Italian study group on Hepatocellular carcinoma.*

### ***Organizative and representative positions in the Veneto Region***

*Member of the Venetian Oncology Network and **Coordinator** of the Gastric cancer Guidelines*

*President of the **Italian Society of Gastroenterology, Veneto Section***

- *Founder of the **Gastroenterology Unit Directors Council***

## **Teaching Activity**

### ***Teaching Books and international teaching activities***

*Author of the chapter on Gastric Cancer of the **Textbook of Gastroenterology "Malattie dell'Apparato Digerente"** Ed. Unigastro, 2004-2006, 2007-2009, 2010-2012 and 2015-18.*

*Lecturer at the:*

- Veterans Administration Center, Alcohol Research and Treatment Center, New York, 1985;*
- University Department of Gastroenterology, Manchester Royal Infirmary, U.K., 1986;*
- Boston University, 1990;*
- New Jersey School of Medicine and Dentistry, 1996.*

*Member of the steering committee of **UNIGASTRO**, Committee of the Italian Teacher of Gastroenterology.*

### ***Additional University Appointments***

*Member of the Scientific **Commission of Medicine***

*Member of the **Surgery, Oncology and Gastroenterology Department Council***

## **Scientific Activity**

### **Publications**


Author of **302** papers quoted in PubMed and 46 book chapter.

**Impact Factor** **1360.52**


**Scopus H index** **46**

**i-10 index** **187**

### **Publications/yr (Median 16)**



### **Citations/yr per anno (Median 295, Total 11238, most quoted paper 631 citations)**



Member **Panel of Experts** of the **Cochrane Reviews Group**.


### **Reserach Fundings**

- DOR (ex 60%) since 1988
- MIUR PRIN (ex 40%), 2000-2002, 2003-2005, 2005-2007
- Veneto Region Grant, 1988
- Grant by the Berlucci Foundation for Oncology Research, 2003-2004
- AIRC Grants in 2005, 2009 and 2014
- Grant Gilead for HBV Research in 2015

### **Medical Societies Membership**

1. Società Italiana di Gastroenterologia (SIGE), since 1985.
2. Associazione Italiana Studio Fegato (AISF) since 1985.
3. European Cancer Prevention Organization (ECP) from 1992 to 2000.
4. ILCA International Liver cancer Association Founding Member
5. EASL European Association for the Study of the Liver, since 2008

- **VicePresident Italian Society of Gastroenterology, 2008 - 2011**
- **Secretary Italian Society of Gastroenterology, 2015 - 2018**
- **Honorary Member Hungarian Society of Gastroenterology, since 2012**



20/3/2017

"Ai sensi e per effetto del D.Lgs. n. 196/2003 'Codice in materia di protezione dei dati personali e sensibili', autorizzo al trattamento dei dati e delle informazioni contenute nel curriculum vitae ai fini del procedimento ECM, consapevole che il CV verrà incluso nell'allegato all'atto della validazione della richiesta di accreditamento, e che sarà visibile nella Banca Dati del sito ECM, accessibile a tutti gli utenti e tramite INTERNET (motori di ricerca). Autorizzo altresì il trattamento ai fini della trasmissione (successiva allo svolgimento dell'evento formativo) alla Commissione Nazionale per la Formazione Continua"



## Prof Fabio Farinati

### Publications within 2017

1. R.Farini, G.Leandro, F.Di Mario, A.Cecchetto, G.Scalabrin, F.Farinati, N.Pennelli, R.Naccarato. Healing of mucosal lesions in early gastric cancer. *Ital J Gastroenterol* 1980; 12: 200-203. (ora DLD). **IF 3.061**
2. R.Farini, G.Leandro, F.Farinati, F.Di Mario, G.Scalabrin, B.Mazzuccato, A.Cecchetto, R.Naccarato. Epithelial dysplasia in endoscopic gastric mucosal biopsies. *Tumori* 1981; 67:589-598. **IF 1.233**
3. F.Farinati, GC Sturniolo, V.Pengo, G.Gurrieri, R.Naccarato. Plasma copper and fibrinogen in primary liver cancer. *Ital J Gastroenterol* 1981;13:269-271.(ora DLD) **IF 3.061**
4. F.Farinati, R.Farini, MW Caldironi, S.Zotti, A.Cecchetto, R.Naccarato. Primary liver cancer: epidemiological and clinical data. *J Exp Clin Cancer Res* 1; 89-91:1982. **IF 5.189**
5. R.Farini, F.Farinati, F.Di Mario, A.Cecchetto, R.Naccarato. Gastric epithelial dysplasia in relapsing and not-relapsing gastric ulcer. *Am J Gastroenterol* 77;844-853, 1982. **IF 9.566**
6. F.Farinati, R.Farini, G.Leandro, F.Di Mario, F.Vianello, L.Lazzaretto, A.Piccoli, R.Naccarato. Changes in the gastric mucosa after ranitidine treatment in duodenal ulcer. *Ital J Gastroenterol* 14, 114-118, 1982.(ora DLD) **IF 3.061**
7. A.Burlina, M.Plebani, C.DeChecchi, M.Zaninotto, F.Farinati, R.Naccarato. Occurrence of an atypical alkaline phosphatase fraction (biliary) in primary liver cancer. *Clin.Biochem.*,16, 343-349, 1983. **IF 2.434**
8. R.Farini, C.Arslan Pagnini, F.Farinati, F.Di Mario, F.Cardin, F.Vianello, M.Rugge, R.Naccarato. Is mild epithelial dysplasia an indication for follow-up? *J.Clin.Gastroenterol.* 5, 307-310, 1983. **IF 3.328**
9. D.Nitti, R.Farini, F.Grassi, F.Cardin, F.Di Mario, A.Piccoli, F.Vianello, F.Farinati, F.Favretti, M.Lise, R.Naccarato. Carcinoembryonic antigen in gastric juice collected during endoscopy. *Cancer* 52, 2334-2337, 1983. **IF 5.997**
10. A.Martin, F.Farinati, N.Bassi, G.Gurrieri, N.Zaramella, D.D'Amico, R.Naccarato. Prostaglandin level in primary liver cell cancer. *Ital.J.Gastroenterol.*, 3, 255-256, 1984.(ora DLD) **IF 3.061**
11. F.Farinati, GC Sturniolo, A.Cecchetto, M.Rugge, R.Naccarato. Granular cell myoblastoma of the esophagus: endoscopic diagnosis and therapy. *Gastrointest. Endosc.*, 31, 22-23, 1985. **IF 6.501**
12. F.Di Mario, F.Farinati, F.Cardin. The risk of gastric dysplasia in medical long term treatment of peptic ulcer disease. *Scand J Gastroenterol*, 20, Suppl.III, 31-35, 1985. **IF 2.526**
13. F.Farinati, ZC Zhou, J.Bellah, CS.Lieber, AJ Garro. Effect of chronic ethanol consumption on activation of nitrosopyrrolidine to a mutagen by rat upper alimentary tract, lung and hepatic tissue. *Drug Metab Dispos* 13, 210-214, 1985. **IF 4.242**
14. F.Vianello, F.Di Mario, G.Battaglia, F.Farinati, F.Cardin, A.Pilotto, R.Cannizzaro, A.Piccoli, P.Valentini, R.Naccarato. Histological changes induced by Pirenzepine in the gastric mucosa of patients with duodenal ulcer: preliminary remarks. *Curr Ther Res Clin E* 38, 40-42, 1985. **IF 0.446**

15. F.Vianello, F.Di Mario, P.Cedaro, M.Plebani, G.Battaglia, F.Farinati, C.Venturi Pasini, R.Naccarato. Subclinical markers in a family with higher prevalence of peptic ulcer. *Ital.J.Gastroenterol.*, 17, 290-292, 1985. (ora DLD) **IF 3.061**
16. Di Mario, G.Battaglia, F.Vianello, A.Piccoli, L.Aggio, A.Pilotto, F.Farinati, R.Naccarato. Predictors of duodenal ulcer relapse: a 12 months study in untreated patients. *Gastroen Clin.Biol.*, 9, 750-751, 1985. **IF 1.140**
17. C.Venturi, M.Bortolami, F.Di Mario, F.De Lazzari, F.Vianello, F.Farinati, M.Plebani, R.Naccarato. Serum pepsinogen group I levels and HLA-B22: a genetic association in a subgroup of duodenal ulcer patients. *Ital.J.Gastroenterol.*, 18, 77-78, 1986. (ora DLD) **IF 3.061**
18. F.Cardin, F.Farinati, F.Di Mario, C.Arslan Pagnini, M.Rugge, G.Penon, R.Naccarato. Dysplasie epithelial gastrique: resultats du depistage et d'un surveillance sistematique. *Acta Endoscopica*, 16, 175-183, 1986. **IF 0.161**
19. G.Battaglia, F.Di Mario, A.Piccoli, F.Vianello, F.Farinati, R.Naccarato. Clinical markers of slow healing and relapsing gastric ulcer. *Gut*, 28, 210-215, 1987. **IF 16.658**
20. AJ Garro, N.Espina, F.Farinati, M.Salvagnini. The effects of chronic ethanol consumption on carcinogen metabolism and on O6-methylguanine transferase activity-mediated repair of alkylated DNA. *Alcohol Clin.Exp.Res.*, 10, 73s-77s, 1987. **IF 2.716**
21. F.Farinati, F.Cardin, F.Di Mario, GA Sava, A.Piccoli, F.Costa, G.Penon, R.Naccarato. Perendoscopic gastric juice pH determination. Simple method for increasing accuracy in diagnosing chronic atrophic gastritis. *Gastrointest.End.*, 33, 293-297, 1987. **IF 6.501**
22. F.Di Mario, G.Battaglia, F.Farinati, F.Cardin, P.Valentini, R.Naccarato. Non-induction of histological changes in gastric mucosa of duodenal ulcer patients by pirenzepine. *Clin.Trials*, 24, 365-368, 1987. **IF 2.715**
23. F.Farinati, F.Cardin, F.Di Mario, F.Vianello, G.Battaglia, C.Arslan Pagnini, R.Cannizzaro, GA Sava, M.Rugge, R.Naccarato. Early and advanced gastric cancer during follow-up of apparently benign gastric ulcer: significance of the presence of epithelial dysplasia. *J. Surg.Oncol.*, 36, 263-267, 1987. **IF 2.993**
24. F.Farinati, F.Cardin, F.Di Mario, F.Costa, M.Scapolo, C.Venturi Pasini, M.Bortolami, F.De Lazzari, R.Naccarato. Genetic, dietary and enviromental factors in the pathogenesis of gastric cancer. Study of a high incidence family. *Ital.J.Gastroenterol.*, 19, 321-324, 1987. (ora DLD) **IF 3.061**
25. F.Farinati, D.Nitti, F.Cardin, F.Di Mario, F.Costa, C.Rossi, A.Marchett, M.Lise, R.Naccarato. CA 19-9 determination in gastric juice: role in identyfying gastric cancer and high risk patients. *Eur.J.Cancer Clin.Oncol.* 24, 923-927, 1988.
26. F.Farinati, F.Cardin, F.Di Mario, G.Battaglia, R.Cannizzaro, G.Penon, R.Naccarato. Gastric ulcer and stomach aging: pathophysiology and clinical implications. *Gerontology*, 34, 297-303, 1988. **IF 4.252**
27. F.Farinati, M.Salvagnini, R.Naccarato. Ethanol first-pass metabolism may protect the liver but endangers upper gastrointestinal tract mucosa. *Ital.J.Gastroenterology*, 20, 291, 1988. (ora DLD) **IF 3.061**
28. F.Farinati, M.Salvagnini, AJ Garro, R.Naccarato. Ethanol and carcinogenesis: promoter, co-carcinogen or innocent bystander? *Ital.J.Gastroenterol.* 20, 322-330, 1988. (ora DLD) **IF 3.061**



29. G.Battaglia, F.Di Maria, R.Cannizaro, F.Farinati, D.Braghetto, G.La Rosa, A.Martin, R.Naccarato. Gastric and duodenal ulcer in the same patient. *Acta Gastroenterol.Belg*, Vol. LI, 322-328, 1988. **IF 0.632**
30. F.Farinati, F.Cardin, F.Di Mario, F.Valiante, C.Arslan Pagnini, M.Rugge, R.Baffa, R.Naccarato. Follow-up in gastric dysplasia patients. *Am.J.Surg.Pathol.* 113, 173-174, 1989. **IF 5.363**
31. F.Farinati, CS Lieber, AJ Garro. Effects of chronic ethanol consumption on carcinogen activating and detoxifying systems in rat upper alimentary tract tissue. *Alcohol Clin.Exp. Res.*, 13, 357-360, 1989. ) **IF 2.716**
32. M.Lise, D.Nitti, A.Marchet, H.Kalamian, A.Fornasiero, M.Fiorentino, F.Farinati, F.Di Mario. Adjuvant chemotherapy and chemoimmunotherapy for gastric carcinoma. *Ital.J.Gastroenterol.*, 21, 164-171, 1989. (ora DLD) **IF 3.061**
33. F.Farinati, M.Plebani, D.Faggian, F.Di Mario, MC Fanton, F.Valiante, A.Burlina, R.Naccarato. TAG-72 serum determination in early and advanced gastric cancer. *Int.J.Cancer*, 44, 378-379, 1989. **IF 6.513**
34. F.Di Mario, S.Glorioso, R.Pagano, R.Cannizzaro, F.Farinati, PF Gambari, F.Vianello, S.Todesco, R.Naccarato. Histological modifications of gastric mucosa and functional correlations in rheumatoid arthritis. *Curr. Ther. Res. Clin Exp*, 46, 1153-1160, 1989. **IF 0.446**
35. F.Farinati, V.Lima, R.Naccarato, AJ Garro. Mutagenic activity in gastric juice and urine of subjects with chronic atrophic gastritis, gastric epithelial dysplasia and gastric cancer. *Cancer Lett.* 48, 169-175, 1989. **IF 6.375**
36. M.Chiamonte, F.Farinati, S.Faggioli, S.Ongaro, V.Aneloni, N.De Maria, R.Naccarato. Antibody to hepatitis C virus in hepatocellular carcinoma. *Lancet*, I, 301-302, 1990. **IF 47.831**
37. A.Martin, I.Castagliuolo, G.Mastropaolo, G.Del Favero, F.Di Mario, F.Farinati, G.Sturniolo, A.Cecchetto, R.Naccarato. Cholestatic jaundice as the presenting symptom of small cell lung cancer. *Ital. J. Gastroenterol.*, 22,36-39, 1990. (ora DLD) **IF 3.061**
38. F.Vianello, F.Di Mario, A.Vio, P.Tessaro, P.Pasqualetti, PL Del Santo, F.Farinati, R.Naccarato. The effect of full-dose famotidine therapy on mucus and pepsin concentrations. *Curr.Ther. Res.*, 48, 91-95, 1990. **IF 0.446**
39. F.Farinati, G.Annoni, MMF Donato, P.Nardelli, A.Bertozzo, N. De Maria, S.Zotti, M.Salvagnini, D.Martinez, R.Naccarato. Diagnostic and prognostic value of the determination of the aminopropeptide of type III procollagen in patients with primary liver cancer. *J.Gastroenterol.Hepatol.*, 5, 633-638, 199°. **IF 3.452**
40. F.Farinati, M.Salvagnini, N. De Maria, A.Fornasiero, M.Chiamonte, L.Rossaro, R.Naccarato. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. *J.Hepatol*, 11, 297-301, 1990. **IF 12.486**
41. F.Farinati, J.Holmgren, F.Di Mario, F.Cardin, F.Valiante, MC Fanton, G.Della Libera, D.Nitti, M.Plebani, B.Crestani, R.Naccarato. CA 50 determination in body fluids: can we screen patients at risk for gastric cancer?. *Int.J.Cancer*, 47, 7-11, 1991. **IF 6.513**
42. F.Farinati, S.Faggioli, N.De Maria, S.Zotti, M.Chiamonte, M.Salvagnini, R.Naccarato. Risk of hepatocellular carcinoma in alcoholic cirrhosis. *Liver Int.*, 11, 190 - 191, 1991. **IF 4.116**
43. F.Farinati, N.De Maria, M.Chiamonte, S.Faggioli, M.Salvagnini, R.Naccarato. Hormonal treatment of hepatocellular carcinoma. *J.Hepatol.* 12, 402, 1991 (Letter). **IF 12.486**
44. F.Farinati, M.Rugge, F.Valiante, R.Baffa, F.Di Mario, R.Naccarato. Gastric epithelial dysplasia. *Gut*, 32, 457, 1991 (Letter). **IF 16.658**

45. F.Farinati, F.Di Mario, M.Plebani, R.Cielo, MC Fanton, F.Valiante, M.Masiero, M.De Boni, G.Della Libera, A.Burlina, R.Naccarato. Pepsinogen A/Pepsinogen C or Pepsinogen A multiplied by gastrin in the diagnosis of gastric cancer? *Ital.J.Gastroenterol.*, 223, 194-196, 1991.(ora DLD) **IF 3.061**
46. Rugge M., Farinati F, Di Mario F, Baffa R, Valiante F, Cardin F. Gastric epithelial dysplasia: A prospective multicenter follow-up study from the Intedisciplinary group on gastric epithelial dysplasia. *Hum Pathol.*, 22: 1002-1008, 1991. **IF 3.014**
47. R.Naccarato, F.Farinati. Hepatocellular carcinoma, alcohol and cirrhosis: facts and hypotheses. *Digest Dis.Sciences*, 36, 1137-1142, 1991. **IF 2.875**
48. M.Rugge, R.Baffa, F.Farinati, F.Di Mario, M.Guido, F.Valiante, V.Ninfo. Epithelial dysplasia in atrophic gastritis. Bioptical follow-up study. *Ital.J. Gastroenterol.*, 23, 70-73, 1991. (ora DLD) **IF 3.061**
49. F.Farinati, M.Zordan, R.Cardin, AG Levis, D.Nitti, M.Lise, F.Valiante, R.Naccarato. Direct involvement of human gastric mucosa in the activation of alimentary procarcinogens. *Eur.J.Cancer Prev.*, 1, 43-48, 1991. **IF 2.556**
50. F.Farinati, F.Turatello, MC Fanton, G.Della Libera, F.Valiante, N.De Maria, F.Di Mario, R.Naccarato. Chronic atrophic gastritis: which is the pathogenetic role of alcohol abuse and smoking? *Alcologia*, 1, 23-28, 1992.
51. F.Farinati, S.Fagioli, N.De Maria, M.Chiamonte, V.Aneloni, S.Ongaro, M.Salvagnini, R.Naccarato. Anti-HCV positive hepatocellular carcinoma in cirrhosis. Prevalence, risk factors and clinical features. *J.Hepatol.*, 14, 183-187, 1992. **IF 12.486**
52. F.Farinati, N.De Maria, A.Fornasiero, M.Salvagnini, S.Fagioli, M.Chiamonte, R.Naccarato. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. *Digest.Dis.Sciences*, 37, 659-662, 1992. **IF 2.875**
53. G.Del Favero, F.Farinati, F.Di Mario, M.Plebani, D.Basso, F.Valiante, T.Meggiato, G.Della Libera, C.Fabris, MC Fanton, C.Angonese, N.De Maria, A.Pannucci, A.Burlina, R.Naccarato. Tumor markers in gastrointestinal malignancies: an up-date. *Eur.J.Cancer Prev.*, 1, Suppl. 3, 59-69, 1992. **IF 2.556**
54. F.Farinati, R.Cardin, M.Zordan, F.Valiante, AJ Garro, P.Burra, P.Venier, D.Nitti, AG Levis, R.Naccarato. Alcohol metabolism in the upper digestive tract: its implications with respect to carcinogenesis. *Eur.J.Cancer Prev*, 1, Suppl.3, 25-32, 1992. **IF 2.556**
55. F.Di Mario, M.Plebani, L.Gottardello G.Battaglia, F.Vianello, F.Farinati, G.Del Favero. Role of serum fasting gastrin in screening for hypergastrinemic syndromes in duodenal ulcer disease. *Clin.Biochem*, 25,121-124, 1992. **IF 2.434**
56. F.Farinati e il GISU (Gruppo Interdisciplinare per lo Studio dell'Ulcera). Sucralfate, ranitidine and no treatment in gastric ulcer management. A multicenter, prospective, randomized, 24-month follow-up with a study of risk factors of relapse. *Digestion*, 53: 72-78, 1992. **IF 2.088**
57. P.Dotto, F.Farinati, G.Battaglia, Abdolhossein Esmailou, F.Vianello, G.Della Libera, F.Di Mario. Thrice-yearly rhythm of duodenal ulcer disease. *Current Therapeutic Research*, 53, 648-653, 1992. **IF 0.446**
58. F.Farinati e il GISU (Gruppo Interdisciplinare per lo Studio dell'Ulcera). Nizatidine 150 mg at night in the prophylaxis of gastric ulcer relapse: a 12-month prospective, randomized, double blind multicentre study versus placebo. *Eur.J.Gastroenterol.Hepatol.*, 5, 97-102, 1993. **IF 1.968**

59. F.Valiante, F.Farinati, PL Del Santo, B.Germana, F.Di Mario, R.Naccarato. Upper gastrointestinal injury caused by diquat. *Gastrointestinal Endoscopy*, 39, 105-106, 1993. IF 6.501
60. F.Farinati, M.Rugge, F.Di Mario, F.Valiante, R.Baffa. Early and advanced gastric cancer in the follow-up of moderate and severe gastric dysplasia patients. A prospective study. *Endoscopy*, 25, 261-264, 1993. IF 5.444
61. F.Farinati, F.Valiante, B.Germanà, G.Della Libera, R.Baffa, M.Rugge, M.Plebani, F.Vianello, F.Di Mario, R.Naccarato. Prevalence of *Helicobacter pylori* infection in patients with precancerous changes and gastric cancer. *Eur.J.Cancer Prev.*, 2, 321-326, 1993. IF 2.556
62. F.Farinati, R.Cardin, G.Della Libera, M.Rugge, F.Di Mario. Lipid peroxidation and anti-oxidant defences in human gastric mucosa, effect of *Helicobacter pylori*. *Eur.J.Gastroenterol. Hepatol.*, 5 (suppl. 2), S9-S11, 1993. IF 1.968
63. Frezza, GE Gerunda, F.Farinati, M.Plebani, A.Giacomin, A.Galligioni, D.Neri, R.Merenda, E.Toniolo, N.De Maria, A.Maffei Faccioli. Sex hormones and trace elements in rat CCL4-induced cirrhosis and hepatocellular carcinoma. *Eur.J.Cancer Prev.*, 2, 357-359, 1993. IF 2.556
64. F.Farinati, S.Formentini, G.Della Libera, F.Valiante, MC Fanton, F.Vianello, A.Pilotto, R.Naccarato. Changes in parietal and mucous cell mass in the gastric mucosa of normal subjects with age: a morphometric study. *Gerontology*, 39, 146-151, 1993. IF 4.252
65. Rugge M, Di Mario F, Cassaro M, Baffa R, Farinati F, Rubio J. Pathology of gastric antrum and body associated with *Helicobacter pylori* infection in nonulcerous patients: is the bacterium a promoter of intestinal metaplasia. *Histopathology*, 22, 9-15, 1993. IF 3.523
66. F.Farinati, M.Plebani, F.Di Mario, F.Valiante, G.Della Libera, MC Fanton, R.Cielo, M.De Boni, A. Burlina, R.Naccarato. Aspartic proteinases and gastrin in the diagnosis of gastric cancer and gastric precancerous changes. *Eur.J.Gastroenterol. Hepatol.*, 5, 707-712, 1993. IF 1.968
67. Farinati F, Dalri L, Rossaro L, Plebani M, Nemetz L, Boccagni P, Bassi N, Naccarato R. Serum and salivary caffeine clearance in cirrhosis. Any role in selection for surgery and timing for transplantation ? *J Hepatol.*, 18, 135-136, 1993. IF 12.486
68. Farinati F, Della Libera G, Valiante F, Fanton MC, Di Mario F, Naccarato R. Gastrin and Gastric Cancer. *Eur.J.Gastroenterol. Hepatol.*, 5, 183-184, 1993. IF 1.968
69. Farinati F e il GISU. Long term treatment of patients with gastric ulcer: sucralfate versus ranitidine versus no treatment. *Current Ther.Res.*, 55, 1117-1125, 1994. IF 0.446
70. F.Farinati, A. Floreani, N.De Maria, S. Fagioli, R.Naccarato, M.Chiamonte. Hepatocellular carcinoma in primary biliary cirrhosis. *J.Hepatol.*, 21, 315-316, 1994. IF 12.486
71. M.Rugge, F.Farinati, R.Baffa, F.Sonego, F.Di Mario, G.Leandro, F.Valiante. Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. *Gastroenterology*, 107, 1288-1296, 1994. IF 18.392
72. F.Farinati, R.Cardin, G.Della Libera, L.Herszenyi, C.Marafin, A.Molari, M.Plebani, M.Rugge, R.Naccarato. The role of anti-oxidants in the chemoprevention of gastric cancer. *Eur.J.Cancer.Prev.*, 3(suppl. 2), 93-97, 1994. IF 1.968
73. EE Frezza, GE Gerunda, F.Farinati, N.De Maria, A.Galligioni, M.Plebani, A.Giacomin, DH.Van Thiel. CCl4-induced liver cirrhosis and hepatocellular carcinoma in rats: relationship to plasma zinc, copper and estradiol levels. *Hepatogastroenterology*, 41, 367-369, 1994. IF 0.792

74. Rugge M, Sonego F, Panozzo M, Baffa R, Rubio J, Farinati F, Nitti D, Ninfo V, Ming SC. Pathology and ploidy in the prognosis of gastric cancer with no extranodal metastasis. *Cancer* 73, 1127-1133, 1994. IF 5.997
75. F.Farinati, N.De Maria, C.Marafin, L.Herszenyi, R.Naccarato. Chemotherapy versus symptomatic treatment for hepatoma. *Gut*, 35, 865, 1994. IF 16.658
76. F.Farinati, N.De Maria, C.Marafin, S.Faggioli, G.Della Libera, R.Naccarato. Hepatocellular carcinoma in alcoholic cirrhosis: is sex hormone imbalance a pathogenetic factor? *Eur. J.Gastroenterol.Hepatol.*, 7, 145-150, 1995. IF 1.968
77. F.Farinati, R.Cardin, N.De Maria, P.E.Lecis, G.Della Libera, P.Burra, C.Marafin, G.C.Sturniolo, R.Naccarato. Zinc, Iron and peroxidation in liver tissue. Cumulative effects of alcohol consumption and virus-mediated damage. A preliminary report. *Biol.Trace Elem.Res.* 47, 193-199, 1995. IF 2.399
78. F.Farinati, R.Cardin, D Della Libera, M.Rugge, L.Herszenyi, F.Di Mario, A.Molari, M.Plebani, R.Naccarato. Determinants for the development of chronic atrophic gastritis and intestinal metaplasia in the stomach. *Eur.J.Cancer Prev.*, 4, 181-186, 1995. IF 2.556
79. M.Rugge, F.Farinati, F.Di Mario. Can we justify resecting all gastric epithelial dysplastic lesions? *Gastroenterology*, 108, 1955-56, 1995. IF 18.392
80. M.Plebani, L.Herszenyi, R.Cardin, G.Roveroni, P.Carraro, M.De Paoli, M.Rugge, W.Grigioni, D.Nitti, R.Naccarato, F.Farinati. Cysteine and serine proteases in gastric cancer. *Cancer*, 76, 367-375, 1995. IF 5.997
81. M.Rugge, G.Leandro, F.Farinati, F.Di Mario, F.Sonego, M.Cassaro, M.Guido, V.Ninfo. Gastric epithelial dysplasia. How clinicopathologic background relates to management. *Cancer*, 76, 376-382, 1995. IF 5.997
82. Farinati F, Cardin R, Mestriner C, Sturniolo GC, Naccarato R. Mechanisms of penicillamine and zinc in the treatment of Wilson's disease. *Am.J.Gastroenterol.*, 90, 2264-2265, 1995. IF 9.566
83. Herszenyi L, Farinati F, Cecchetto A, Marafin C, De Maria N, Cardin R, Naccarato R. Fine-needle biopsy in focal liver lesions: the usefulness of a screening program and the role of cytology and microhistology. *Ital.J.Gastroenterol.*, 27, 473-478, 1995. (ora DLD) IF 3.061
84. Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, Burra P, Floreani A, Cecchetto A, Naccarato R. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. *J.Hepatol.*, 22, 449-465, 1995. IF 12.486
85. Farinati F., Cardin R., D'Errico A, De Maria N, Naccarato R., Cecchetto A, Grigioni W. Hepatocyte proliferative activity in chronic liver damage as assessed by the monoclonal antibody MIB1 Ki67 in archival material: the role of etiology, disease activity, Iron and lipid peroxidation. *Hepatology*, 23, 1468-1475, 1996. IF 13.246
86. Zaninotto M, Ujka F, Lachin M, Bernardi D, Marafin C, Farinati F, Plebani m. Lectin-affinity electrophoresis for the detection of AFP microheterogeneity in patients with hepatocellular carcinoma. *Anticancer Research*, 16, 305-310, 1996. IF 1.937
87. Farinati F. Tamoxifen treatment in hepatocellular carcinoma. *Gastroenterology*, 11, 272-273, 1996 IF 18.392.
88. Rugge M, Cassaro M, Farinati F, Saggiaro A, Di Mario F. Helicobacter pylori and atrophic gastritis: importance of CagA status. *J.Natl. Cancer Inst.* 88, 762-764, 1996. IF 12.589
89. F.Farinati, L.Herszenyi, M.Plebani, P.Carraro, M.De paoli, R. Cardin, G.Riveroni, M.Rugge, D.Nitti, WF.Grigioni, A.D'Errico, R.Naccarato. Increased levels of cathepsin B and L, urokinase

- type plasminogen activator and its inhibitor type I as an early event in gastric carcinogenesis. *Carcinogenesis*, 17, 2581-2587, 1996. IF 5.105
90. Farinati F, Della Libera G, Cardin R, Molari A, Plebani M, Rugge M, Di Mario F, Naccarato R. Gastric antioxidants, nitrites and mucosal lipoperoxidation in chronic gastritis and *Helicobacter pylori* infection. *J.Clin.Gastroenterol.* 22, 275-281, 1996. IF 3.328
91. Farinati F e la Monotematica AISF-OLT Study Group. Liver transplantation in Italy: preliminary 10-year report. *Ital.J.Gastroenterol.*, 28, 343-350, 1996. (ora DLD) IF 3.061
92. F.Farinati, M.Rinaldi, C. Angonese, G. De Franchis, M.Plebani, R.Naccarato. Activation of cytotoxic and natural killer T-cell system in patients with hepatocellular carcinoma and cirrhosis. *Ital.J.Gastroenterol.*, 28: 493-498, 1996. (ora DLD) IF 3.061
93. Farinati F, Cardin R, Naccarato R, Floreani A. Cysteine and glutathione in the liver of patients with primary biliary cirrhosis. *J.Hepatol.*, 25, 123-124, 1996. IF 12.486
94. F.Farinati, G.Dalla Libera, F.Valiante, C.Tanduo, C.Marafin, C.Angonese, D.Nitti, R.Bardini, A.Tropea, G. del Favero, R.Naccarato. Coffee consumption and pancreatic cancer: a cancer controlled case-control study. *Eur.J.Gastroenterol. Hepatol* 1994, 6, 189-191 IF 1.968
95. Farinati F, De Maria N, Marafin C, Herszenyi L, Del Parto S, Rinaldi M, Perini L, Cardin R, Naccarato R. Unresectable hepatocellular carcinoma in cirrhosis. Survival, prognostic factors and unexpected side effects after transcatheter arterial chemoembolization. *Dig.Dis.Sci.* 41, 2332-2339, 1996. IF 2.875
96. A.Floreani, MR Biagini, F.Zappala, F.Farinati, M.Plebani, M.Rugge, C.Surrenti, R.Naccarato. Chronic atrophic gastritis and *helicobacter pylori* infection in primary biliary cirrhosis: a cross sectional study with matching. *Ital.J.Gastroenterol.Hepatol.*, 29:13-17, 1997. (ora DLD) IF 3.061
97. F.Farinati, R.Cardin, G.Della Libera, T.Palotta, M.Rugge, A.Colantoni, G.Gurrieri. Effects of N-acetyl-L-cysteine in patients with chronic atrophic gastritis and non-ulcer dyspepsia: a phase III pilot study. *Curr. Ther.Res.*, 58:724-733, 1997. IF 0.446
98. M.Plebani, L.Herszenyi, P.Carraro, M.De Paoli, G.Roveroni, R.Cardin, Z.Tulassay, R.Naccarato, F.Farinati. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. *Clin.Exp.Metastasis*, 15:418-425, 1997 IF 3.144
99. F.Farinati, M.Rinaldi, S.Del Prato, S.Lana, N.De Maria, D.Paleari, C.Marafin, R.Naccarato. Fasting hyperglycemia following trans-catheter arterial chemoembolization for hepatocellular carcinoma in cirrhosis. *Ital.J.Gastroenterol.Hepatol.*, 29:427-433, 1997. (Ora DLD) IF 3.061
100. G.Berglund, MJ Hill, CPJ Cahill, F.Farinati, A.Giacosa, E De Koster, PI Reed, M. Sobrinho-Simoes, R.Stockbrugger. Consensus statement on diet and gastric cancer. *Eur.J.Cancer Prevention*, 6: 404-407, 1997. IF 2.556
101. F.Farinati, R.Cardin, P.Degan, M.Rugge, F.Di Mario, P.Bonvicini, R.Naccarato. Oxidative DNA accumulation in gastric carcinogenesis. *Gut*, 42, 351-353, 1998. IF 16.658
102. F.Farinati, F. Foschia, F. Di Mario, M.Cassarò, M.Rugge. H-pylori eradication and gastric precancerous lesions. *Gastroenterology*, 115: 512-514, 1998. IF 18.392
103. Farinati F & CLIP Group (Cancer of the Liver Italian Program). Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. *Lancet* 352, ii: 17-20, 1998. IF 47.831
104. F.Farinati, M.Rinaldi, S.Gianni, G.Marin. Transcatheter arterial chemoembolization in hepatocellular carcinoma. *Hepatology*, 28, 5, 1441-2, 1998. IF 13.246

105. Farinati F. and CLIP (Cancer of the Liver Italian Program investigators) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian program Investigators. *Hepatology*, 28, 3, 751-755, 1998. IF 13.246
106. F. Farinati, R. Cardin, P. Degan, N. De Maria, RA Floyd, DH Van Thiel, R. Naccarato. Oxidative DNA damage in circulating leukocytes occurs as an early event in chronic HCV infection. *Free Rad. Biol. Med.*, 27; 1284-1291, 1999. IF 5.606
107. L. Herszenji, M.Plebani, P.Carraro, M.De Paoli, G. Roveroni, R.Cardin, F.Foschia, Z.Tulassay, R.Naccarato, F. Farinati. The role of cysteine and serine proteases in colorectal carcinoma. *Cancer*, 86:1135-42, 1999. IF 5.997
108. A.Floeani, A.Baraggiotta, V.Baldo, T.Menegon, F.Farinati, R.Naccarato. Hepatic and hextrahepatic malignancies in primary biliary cirrhosis. *Hepatology*, 29: 1425-1428, 1999. IF 13.246
109. M.Chiamonte, T.Stroffolini, A.Vian, MA Stazi, A.Floeani, U.Lorenzoni, S.Lo Bello, F.Farinati, R.Naccarato. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. *Cancer*, 85:2132-2137, 1999. IF 5.997
110. M.Rugge, M.Cassaro, G.Leo, F.Farinati. Graham DY. Helicobacter pylori and gastric cancer: both primary and secondary preventive measures are required. *Arch.Intern.Med.* 159:2483-2484, 1999. IF 17.333
111. L. Herszenji, M.Plebani, P.Carraro, M.De Paoli, G. Roveroni, R.Cardin, F.Foschia, Z.Tulassay, R.Naccarato, F. Farinati. Proteases in gastrointestinal neoplastic diseases. *Cl.Chim.Acta*, 291: 171-187, 2000. IF 2.873
112. Farinati F & The Cancer of the liver Italian Program Investigators (CLIP). Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. *Hepatology* 31:840-845, 2000. IF 13.246
113. L.Herszenyi, M.Plebani, P.Carraro, M. De Paoli, R.Cardin, F.Di Mario, S. Kusstatscher, R.Naccarato, F.Farinati. Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer. *Am.J.Gastroenterol.*, 92 , 843-847, 1997. IF 9.566
114. Rugge M, Cassaro M, Farinati F, Di Mario F. Diagnosis of gastric carcinoma in Japan and Western countries. *Lancet*, 350:448, 1997. IF 47.831
115. Farinati F, Gianni S. Surveillance for hepatocellular carcinoma in cirrhosis: is it cost-effective? *Eur J Cancer Prev.* 2001 Feb;10(1):111-5. IF 2.556
116. Raimondo G, Balsano C, Craxi A, Farinati F, Mondello M, Pollicino T, Squadrito G, Tiribelli C. Occult hepatitis B virus infection. *Dig Liver Dis.* 2000 Dec;32(9):822-6. IF 3.061
117. Farinati F, Cardin R, Fiorentino M, D'Errico A, W, Cecchetto A, Naccarato R. Imbalance between cytoproliferation and apoptosis in hepatitis C virus related chronic liver disease. *J Viral Hepat.* 2001 Jan;8(1):34-40. IF 4.122
118. Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. *Cancer.* 2000 Dec 1;89(11):2266-73. IF 5.997
119. Crespi M, Farinati F. Gastroenterological oncology: a top priority. *Dig Liver Dis.* 2000 Nov;32(8):743-4. IF 3.061
120. Cardin R, Saccoccio G, Mansutti F, Bellentani S, Farinati F, Tiribelli C. DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an open population study. *J.Hepatol.*, 2001, 34: 587-592. IF 12.486



121. Ruge M, Russo V, Busatto G, Genta Rm, Di Mario F, Farinati F, Graham DY. The phenotype of gastric mucosa coexisting with Barrett's oesophagus. *J.Clin.Pathol*, 2001;54:456-460. **IF 2.687**
122. Corleto VD, Panzot F, Falconi M, Cannizzaro R, Angeletti S, Moretti A, Delle Fave G, Farinati F. Digestive Neuroendocrine tumors: diagnosis and treatment in Italy. A survey by the Oncology Study Section of the Italian society of Gastroenterology. *Dig.Liv.Dis* 2001;33:217-221 **IF 3.061**
123. Fagioli S, Minniti F, Pevere S, Farinati F, Burra P, Livi U, Naccarato R, Chiaramonte M. HBV and HCV infections in heart transplant recipients. *J.Heart Lung transpl.* 2001, 20:718-724 **IF 7.114**
124. Farinati F, Gianni S, Marin G, Fagioli S, Rinaldi M, Naccarato R. Does the choice of treatment influence survival of patients with small hepatocellular carcinoma in compensated cirrhosis ? *Eur.J.Gastroenterol.Hepatol.* 2001, 13:1217-1224. **IF 1.968**
125. Farinati F, Gianni S, De Giorgio M, Fiorentini S. Megestrol treatment in patients with hepatocellular carcinoma. *Br.J.Cancer*, 2001;85:1607-8 **IF 6.176**
126. Cardin R, D'Errico A, Fiorentino M, Cecchetto A, Naccarato R, Farinati F. Hepatocyte proliferation and apoptosis in relation to oxidative damage in alcohol-related liver disease. *Alcohol Alcohol.* 2002, 37:43-48. **IF 2.757**
127. Trevisani F, De Notaris S, Rapaccini G, Farinati F, Benvegnù L, Zoli M, Grazi GL, Del P P, Di Nola H, Bernardi M. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patients survival. (Italian experience). *Am.J.Gastroenterol*, 2002, 97:734-744. **IF 9.566**
128. Farinati F, Cardin R, Fiorentino M. Apoptosis in alcoholic hepatitis. *J.Hepatol.*, 2002, 36:570-1. **IF 12.486**
129. Perrone F Gallo C, Daniele B, Gaeta GB, Izzo F, Capuano G, Adinolfi LE, Mazzanti R, Farinati F et al.. Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 Multicenter randomised controlled trial. *Curr.Pharm.Des.* 2002, 8:1013-9. **IF 2.611**
130. Floreani A, Paternoster D, Mega A, Farinati F, Plebani M, Baldo V, Grella P. Sex hormone profile and endometrial cancer risk in primary biliary cirrhosis: a case-control study. *Eur J Obstet Gynecol Reprod Biol.* 2002;103(2):154-7. **IF 1.666**
131. Farinati F, Cardin R, Bortolami M, Grottola A, Manno M, Colantoni A, Villa E. Estrogens receptors and oxidative damage in the liver. *Mol Cell Endocrinol.* 2002;193(1-2):85-8. **IF 3.754**
132. Bortolami M, Venturi C, Giacomelli L, Scalerta R, Bacchetti S, Marino F, Floreani A, Lise M, Naccarato R, Farinati F. Cytokine, infiltrating macrophage and T cell-mediated response to development of primary and secondary human liver cancer. *Dig Liver Dis.* 2002;34(11):794-801. **IF 3.061**
133. Ruge M, Cassaro M, Pennelli G, Russo VM, Di Mario F, Farinati F. Pathology and cost effectiveness of endoscopy surveillance for premalignant gastric lesions. *Gut.* 2003;52(3):453-4. **IF 16.658**
134. Farinati F, Cardin R, Russo VM, Busatto G, Franco M, Ruge M. Helicobacter pylori CagA status, mucosal oxidative damage and gastritis phenotype: a potential pathway to cancer? *Helicobacter.* 2003;8(3):227-34. **IF 3.429**

135. Farinati F, Cardin R, D'inca R, Naccarato R, Sturniolo GC. Zinc treatment prevents lipid peroxidation and increases glutathione availability in Wilson's disease. *J Lab Clin Med.* 2003 Jun;141(6):372-7. **IF 2.795**
136. Rugge M, Cassaro M, Di Mario F, Leo G, Leandro G, Russo VM, Pennelli G, Farinati F. The long term outcome of gastric non-invasive neoplasia. *Gut.* 2003;52(8):1111-1116. **IF 16.658**
137. Nitti D, Marchet A, Olivieri M, Ambrosi A, Mencarelli R, Farinati F, Belluco C, Lise M. Lymphadenectomy in patients with gastric cancer. A critical review. *Suppl Tumori.* 2003; 2(5): S35-8. **IF 1,233**
138. Rugge M, Cassaro M, Pennelli G, Leandro G, Di Mario F, Farinati F. Atrophic gastritis: pathology and endoscopy in the reversibility assessment. *Gut.* 2003 Sep; 52(9): 1387-8. **IF 16.658**
139. Farinati F, Cardin R, Bortolami M, Rugge M. The mechanisms underlying hepatitis C virus genotype 3-mediated liver damage. *J Hepatol.* 2003; 39(2): 292-4 **IF 12.486**
140. Cillo U, Vitale A, Bassanello M, Boccagni P, Brolese A, Zanus G, Burra P, Faggioli S, Farinati F, Rugge M, D'Amico DF. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. *Ann Surg.* 2004; 239(2): 150-9. **IF 8.980**
141. Farinati F, Marino D, De Giorgio M, Trevisani F. A reappraisal of the Barcelona Clinic Liver Cancer model: natural history of untreated 'intermediate stage' hepatocellular carcinoma. *J Intern Med.* 2004 (6):529-30. **IF 7.598**
142. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Crax A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. *Gastroenterology.* 2004 Jan; 126(1): 102-10. **IF 18.392**
143. Farinati F, Cardin R, Russo VM, Busatto G, Franco M, Falda A, Mescoli C, Rugge M. Differential effects of *Helicobacter pylori* eradication on oxidative DNA damage at the gastroesophageal junction and at the gastric antrum. *Cancer Epidem Biomar & Prev,* 2004 (11):1722-8. **IF 4.142**
144. Farinati F, Cardin R, Bortolami M, Rugge M. Up and down regulation of apoptosis in hepatitis C virus-related liver damage. *J Hepatol.* 2004;41(5):883-5. **IF 12.486**
145. Trevisani F, Cantarini MC, Labate AM, De Notariis S, Rapaccini G, Farinati F, Del Poggio P, Di Nolfo MA, Benvegna L, Zoli M, Borzio F, Bernardi M; Italian Liver Cancer (ITALICA) group. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. *Am J Gastroenterol.* 2004;99(8):1470-6. **IF 9.566**
146. Cassaro M, Pennelli G, Rugge M, Farinati F, Zaninotto G. Gastric precancerous lesion follow up based on pathological evidence *J Clin Pathol.* 2004;57(9):1007-8. **IF 2.687**
147. Rugge M, Ingravallo G, Farinati F, Russo VM, Zaninotto G, Alvisi V. CDX2 homeotic gene expression in gastric noninvasive neoplasia *Am J Surg Pathol.* 2004 Jun;28(6):834-5. **IF 5.363**
148. Zambon CF, Basso D, Navaglia F, Mazza S, Razetti M, Fogar P, Greco E, Gallo N, Farinati F, Rugge M, Plebani M. Non-invasive diagnosis of *Helicobacter pylori* infection: simplified <sup>13</sup>C-urea breath test, stool antigen testing, or DNA PCR in human feces in a clinical laboratory setting? *Clin Biochem.* 2004 (4):261-7. **IF 2.434**
149. Zambon CF, Basso D, Navaglia F, Falda A, Belluco C, Fogar P, Greco E, Gallo N, Farinati F, Cardin R, Rugge M, Di Mario F, Plebani M. Increased risk of noncardia gastric cancer



- associated with proinflammatory cytokine gene polymorphisms. *Gastroenterology*. 2004 (1):382-4. **IF 18.392**
150. Bortolanza S, Qian C, Kramer MG, Gomar C, Prieto J, Farinati F, Hernandez-Alcoceba R. An oncolytic adenovirus controlled by a modified telomerase promoter is attenuated in telomerase-negative cells, but shows reduced activity in cancer cells. *J Mol Med*. 2005;83(9):736-47. **IF 4.686**
151. Franco M, Rugge M, D'Andrea E, Mescoli C, Menin C, Farinati F. Gastric mucosa-associated lymphoid tissue lymphoma and *Helicobacter pylori*: scratch and win. *Scand J Gastroenterol*. 2005;40(1):115-9. **IF 2.526**
152. Stefani AL, Barzon L, Castagliuolo I, Guido M, Pacenti M, Parolin C, Farinati F, Palù G. Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma. *J Hepatol*. 2005;42(5):728-35. **IF 12.486**
153. Nitti D, Marchet A, Mammano E, Ambrosi A, Belluco C, Mencarelli R, Maino M, Marconato G, Farinati F, Lise M. Extended lymphadenectomy (D2) in patients with early gastric cancer. *Eur J Surg Oncol*. 2005 (8):875-81. **IF 3.184**
154. Rugge M, Nitti D, Farinati F, di Mario F, Genta RM. Non-invasive neoplasia of the stomach Non-invasive neoplasia of the stomach. *Eur J Gastroenterol Hepatol*. 2005 (11):1191-1196. **IF 1.968**
155. Zaninotto G, Cassaro M, Pennelli G, Battaglia G, Farinati F, Ceolin M, Costantini M, Ruol A, Guirroli E, Rizzetto C, Portale G, Ancona E, Rugge M. Barrett's epithelium after antireflux surgery. *J Gastrointest Surg*. 2005;9(9):1253-60. **IF 2.963**
156. Rugge M, Bersani G, Bertorelle R, Pennelli G, Russo VM, Farinati F, Bartolini D, Cassaro M, Alvisi V. Microsatellite instability and gastric non-invasive neoplasia in a high risk population in Cesena, Italy. *J Clin Pathol*. 2005 (8):805-10. **IF 2.687**
157. Gianni S, Cecchetto A, Altavilla G, Ragazzi R, Bertazzo M, De Giorgio M, Baldan A, Faggioli S, Farinati F. Tumour staging, morphology and p53 overexpression concur in predicting survival in hepatocellular carcinoma. *J Intern Med*. 2005 (4):367-73. **IF 7.598**
158. Cantarini MC, Trevisani F, Morselli AM, Rapaccini G, Farinati F, Del Poggio P, Di Nolfo MA, Benvegna L, Zoli M, Borzio F, Bernardi M; Italian Liver Cancer (ITA.LI.CA) group. Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. *Am J Gastroenterol*. 2006;101(1):91-8. **IF 9.566**
159. Angonese C, Baldan A, Cillo U, D'Alessandro A, De Antoni M, De Giorgio M, Masotto A, Marino D, Massani M, Mazzucco M, Miola E, Neri D, Paccagnella D, Pivetta G, Tommasi L, Tremolada F, Tufano A, Zanusi G, Farinati F. Complications of radiofrequency thermal ablation in hepatocellular carcinoma: what about "explosive" spread? *Gut*. 2006;55(3):435-6. **IF 16.658**
160. Burra P, Buda A, Livi U, Rigotti P, Zanusi G, Calabrese F, Caforio A, Menin C, Canova D, Farinati F, Luciana Aversa SM. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection? *Eur J Gastroenterol Hepatol*. 2006;18(10):1065-70. **IF 1.968**
161. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanusi G, Neri D, Boccagni P, Srsen N, D'Amico F, Ciarleglio FA, Brida A, D'Amico DF. Prospective validation of the Barcelona Clinic Liver Cancer staging system. *J Hepatol*. 2006;44(4):723-31. **IF 12.486**

162. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegno L, Zoli M, Borzio F, Bernardi M, Trevisani F. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? *Am J Gastroenterol*. 2006;101(3):524-32. **IF 9.566**
163. Pastorelli D, Cartei G, Zustovich F, Marchese F, Artioli G, Zovato S, Binato S, Ceravolo R, Cingarlini S, Salmaso F, Mattiazzi M, Sanavio C, Farinati F, Zanus G, Cillo U. Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature. *Ann Oncol*. 2006;17 Suppl 5:v153-v157. **IF 11.855**
164. Pignata S, Gallo C, Daniele B, Elba S, Giorgio A, Capuano G, Adinolfi LE, De Sio I, Izzo F, Farinati F, Del Naja C, Stanzione M, Castiglione F, Marone G, Cuomo O, Felder M, Gaeta GB, De Maio E, Di Maio M, Signoriello G, Perrone F; CLIP Investigators. Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP). *Crit Rev Oncol Hematol*. 2006;59(3):243-9. **IF 5.980**
165. Giannini EG, Risso D, Testa R, Trevisani F, Di Nolfo MA, Del Poggio P, Benvegno L, Ludovico Rapaccini G, Farinati F, Zoli M, Borzio F, Caturelli E; Italian Liver Cancer (ITA.LI.CA.) Group. Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma. *Clin Gastroenterol Hepatol*. 2006;4(11):1378-84. **IF 7.680**
166. Cillo U, Vitale A, Brolese A, Zanus G, Neri D, Valmasoni M, Bonsignore P, Grigoletto F, Burra P, Farinati F, D'Amico DF. Partial hepatectomy as first-line treatment for patients with hepatocellular carcinoma. *J Surg Oncol*. 2007;95(3):213-20. **IF 2.993**
167. Baldan A, Marino D, DE Giorgio M, Angonese C, Cillo U, D'Alessandro A, Masotto A, Massani M, Mazzucco M, Miola E, Neri D, Paccagnella D, Pivetta G, Stellato A, Tommasi L, Tremolada F, Tufano A, Zanus G, Farinati F; Gene - Gruppo Epatocarcinoma NORD-EST. Percutaneous radiofrequency thermal ablation for hepatocellular carcinoma. *Aliment Pharmacol Ther*. 2006;24(10):1495-501. **IF 7.286**
168. Farinati F, Cardin R, Bortolami M, Guido M, Rugge M. Oxidative damage, pro-inflammatory cytokines, TGF-alpha and c-myc in chronic HCV-related hepatitis and cirrhosis. *World J Gastroenterol*. 2006;12(13):2065-9. **IF 3.365**
169. Trevisani F, Magini G, Santi V, Morselli-Labate AM, Chiara Cantarini M, Anna Di Nolfo M, Del Poggio P, Benvegno L, Rapaccini G, Farinati F, Zoli M, Borzio F, Giovanni Giannini E, Caturelli E, Bernardi M; for the Italian Liver Cancer (ITA.LI.CA) Group. Impact of Etiology of Cirrhosis on the Survival of Patients Diagnosed With Hepatocellular Carcinoma During Surveillance. *Am J Gastroenterol* 2007;102(5):1022-31. **IF 9.566**
170. Zaninotto G, Minnei F, Guirrola E, Ceolin M, Battaglia G, Bellumat A, Betetto G, Bozzola L, Cassaro M, Cataudella G, Dal Bo N, Farinati F, Florea G, Furlanetto A, Galliani E, Germana B, Guerini A, Macri E, Marcon V, Mastropaolo G, Meggio A, Miori G, Morelli L, Murer B, Norberto L, Togni R, Valiante F, Rugge M. The Veneto Region's Barrett's Oesophagus Registry: aims, methods, preliminary results. *Dig Liver Dis*. 2007;39(1):18-25. **IF 3.061**
171. Ulazzi L, Sabbioni S, Miotto E, Veronese A, Angusti A, Gafa R, Manfredini S, Farinati F, Sasaki T, Lanza G, Negrini M. Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer. *Mol Cancer*. 2007;6:17. **IF 6.204**
172. Cillo U, Vitale A, Grigoletto F, Gringeri E, D'Amico F, Valmasoni M, Brolese A, Zanus G, Srsen N, Carraro A, Burra P, Farinati F, Angeli P, D'Amico DF. Intention-to-Treat Analysis of

- Liver Transplantation in Selected, Aggressively Treated HCC Patients Exceeding the Milan Criteria. *Am J Transplant* 2007;7(4):972-81. IF 6.165
173. Cassaro M, Rugge M, Tieppo C, Giacomelli L, Velo D, Nitti D, Farinati F. Indefinite for non-invasive neoplasia lesions in gastric intestinal metaplasia: the immunophenotype. *J Clin Pathol.* 2007;60(6):615-21. IF 2.687
174. Farinati F, Sergio A, Baldan A, Zucchetto P, Corleto VD. Octreotide and hepatocellular carcinoma. *Br J Cancer.* 2007;96(11):1778-9. IF 6.176
175. Trevisani F, Santi V, Gramenzi A, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Farinati F, Zoli M, Borzio F, Giovanni Giannini E, Caturelli E, Bernardi M; Italian Liver Cancer group. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? *Am J Gastroenterol* 2007;102(11):2448-57. IF 9.566
176. Farinati F, Cardin R, Bortolami M, Burra P, Russo FP, Rugge M, Guido M, Sergio A, Naccarato R. Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma. *J Viral Hepat.* 2007;14(12):821-9. IF 4.122
177. Burra P, Tomat S, Villa E, Gasbarrini A, Costa AN, Conconi MT, Forbes SJ, Farinati F, Cozzi E, Alison MR, Russo FP; Italian Association for the Study of the Liver (AISF). Experimental hepatology applied to stem cells. *Dig Liver Dis.* 2008;40(1):54-61. IF 3.061
178. Bortolami M, Cardin R, Kotsafti A, Farinati F. TGF-beta and hepatocellular carcinoma. *Hepatology.* 2008;47(3):1095. IF 13.246
179. Guido M, Roskams T, Pontisso P, Fassan M, Thung SN, Giacomelli L, Sergio A, Farinati F, Cillo U, Rugge M. Squamous cell carcinoma antigen in human liver carcinogenesis. *J Clin Pathol.* 2008;61(4):445-7. IF 2.687 non 9.566
180. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomini A, Farinati F. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. *Am J Gastroenterol.* 2008;103(4):914-21. IF 9.566
181. Farinati F, Cardin R, Cassaro M, Bortolami M, Nitti D, Tieppo C, Zaninotto G, Rugge M. *Helicobacter pylori*, inflammation, oxidative damage and gastric cancer: a morphological, biological and molecular pathway. *Eur J Cancer Prev.* 2008;17(3):195. IF 2.556
182. Bortolami M, Kotsafti A, Cardin R, Farinati F. Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease. *J Viral Hepat.* 2008;15(7):515-22. IF 4.122
183. Farinati F, Cardin R, Bortolami M, Nitti D, Basso D, de Bernard M, Cassaro M, Sergio A, Rugge M. Oxidative DNA damage in gastric cancer: CagA status and OGG1 gene polymorphism. *Int J Cancer.* 2008;123(1):51-5. IF 6.513
184. Herszényi L, Farinati F, Cardin R, István G, Molnár LD, Hritz I, De Paoli M, Plebani M, Tulassay Z. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. *BMC Cancer.* 2008;8:194. IF 3.288
185. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med.* 2008 24;359(4):378-90 IF 72.406

186. De Martin E, Senzolo M, Boninsegna S, Guido M, Masier A, Germani G, Tomat S, Brolese A, Neri D, Cillo U, Gambato M, Russo FP, Farinati F, Burra P. HCV histological recurrence and survival following liver transplantation in patients with and without hepatocellular carcinoma. *Transplant Proc.* 2008;40(6):1974-5 **IF 0.908**
187. Herszényi L, István G, Cardin R, De Paoli M, Plebani M, Tulassay Z, Farinati F. Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers. *Eur J Cancer Prev.* 2008;17(5):438-45 **IF 2.556**
188. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Cavazza A, Caballería L, Floreani A, Farinati F, Bruguera M, Caroli D, Parés A. *Hepatology.* 2009;50(4):1162-8. **IF 13.246**
189. Giannini EG, Marabotto E, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M; Italian Liver Cancer (ITALICA) Group. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. *Clin Gastroenterol Hepatol.* 2009;7(5):580-5. **IF 7.680**
190. Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? Farinati F, Sergio A, Giacomini A, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Zoli M, Borzio F, Giannini EG, Caturelli E, Trevisani F; Italian Liver Cancer group. *Eur J Gastroenterol Hepatol.* 2009;21(10):1212-8. **IF 1.968**
191. Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. Vitale A, Saracino E, Boccagni P, Brolese A, D'Amico F, Gringeri E, Neri D, Srsen N, Valmasoni M, Zanusi G, Carraro A, Violi P, Pauletto A, Bassi D, Polacco M, Burra P, Farinati F, Feltracco P, Romano A, D'Amico DF, Cillo U. *Transplant Proc.* 2009;41(4):1260-3. **IF 0.908**
192. Gastrointestinal stromal tumors: report of an audit and review of the literature. Biasco G, Velo D, Angriman I, Astorino M, Baldan A, Baseggio M, Basso U, Battaglia G, Bertin M, Bertorelle R, Bocus P, Brosolo P, Bulzacchi A, Cannizzaro R, Da Dalt GF, Di Battista M, Errante D, Fedrigo M, Frustaci S, Lionetti I, Massani M, Mencarelli R, Montesco MC, Norberto L, Pantaleo MA, Pasquali C, Pastorelli D, Rossi CR, Ruffolo C, Salvagno L, Saponara MS, Vittadello F, Zaccaria F, Zovato S, Farinati F; Section of Oncology of the Italian Society of Gastroenterology; Interdisciplinary GIST Group-G.I.GIST, Veneto Institute of Oncology IOV-IRCCS Azienda Ospedale, University of Padua; GIST Study Group, Bologna University. *Eur J Cancer Prev.* 2009;18(2):106-16. **IF 2.556**
193. Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. Farinati F, Sergio A, Baldan A, Giacomini A, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Zoli M, Borzio F, Giannini EG, Caturelli E, Trevisani F. *BMC Cancer.* 2009; 27: 9-33. **IF 3.288**
194. Vitale A, Volk ML, Pastorelli D, Lonardi S, Farinati F, Burra P, Angeli P, Cillo U. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. *Hepatology.* 2010;51(1):165-73 **IF 13.246**
195. Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. Giannini EG, Bodini G, Corbo M, Savarino V, Risso D, Di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; ITALIAN LIVER CANCER (ITA.LI.CA.) GROUP. *Aliment Pharmacol Ther.* 2010;31(4):493-501. **IF 7.286**

196. Megestrol and embryonic extracts in the treatment of advanced hepatocellular carcinoma: A prospective randomized trial in the pre-sorafenib era. Giacomini A, Sergio A, Vanin V, Tartaro P, Paccagnella D, Mazzucco M, Farinati F. *Hepatol Res.* 2010;40(2):153-60. **IF 2.602**
197. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Mirici-Cappa F, Gramenzi A, Santi V, Zambruni A, Di Micoli A, Frigerio M, Maraldi F, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Farinati F, Zoli M, Borzio F, Giannini EG, Caturelli E, Bernardi M, Trevisani F; Italian Liver Cancer Group. *Gut.* 2010;59(3):387-96. **IF 16.658**
198. Bax inhibitor-1 down-regulation in the progression of chronic liver diseases. Kotsafti A, Farinati F, Cardin R, Burra P, Bortolami M. *BMC Gastroenterol.* 2010;10:35. **IF 2.212**
199. Hepatic spleen nodules (HSN). Mescoli C, Castoro C, Sergio A, Ruol A, Farinati F, Rugge M. *Scand J Gastroenterol.* 2010;45(5):628-32. **IF 2.526**
200. Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases. Zerbi A, Falconi M, Rindi G, Delle Fave G, Tommasetti P, Pasquali C, Capitanio V, Boninsegna L, Di Carlo V, Farinati F. *American Journal of Gastroenterol.* 2010; 105(6):1421-1429. **IF 9.566**
201. Transarterial chemoembolization in Child-Pugh class B patients with hepatocellular carcinoma: between the devil and the deep blue sea. Giannini EG, Savarino V, Risso D, Di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer group. *Liver Int.* 2010;30(6):923-4. **IF 4.116**
202. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, Di Nolfo MA, Benvegnù L, Farinati F, Zoli M, Giannini EG, Borzio F, Caturelli E, Chiaramonte M, Bernardi M; Italian Liver Cancer (ITA.LI.CA) Group. *J Hepatol.* 2010;53(2):291-7. **IF 12.486**
203. The survival benefit of liver transplantation in hepatocellular carcinoma patients. Cillo U, Vitale A, Volk ML, Frigo AC, Grigoletto F, Brolese A, Zanusi G, D'Amico F, Farinati F, Burra P, Russo F, Angeli P, D'Amico DF. *Dig Liver Dis.* 2010;42(9):642-9. **IF 3.061**
204. Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO). Alvaro D, Cannizzaro R, Labianca R, Valvo F, Farinati F. *Dig Liver Dis.* 2010;42(12):831-8. **IF 3.061**
205. Oxidative stress and inducible nitric oxide synthase induction in carcinogenesis. Farinati F, Picciocchi M, Lavezzo E, Bortolami M, Cardin R. *Dig Dis.* 2010;28(4-5):579-84. **IF 1.775**
206. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. Lombardi G, Zustovich F, Farinati F, Cillo U, Vitale A, Zanusi G, Donach M, Farina M, Zovato S, Pastorelli D. *Cancer.* 2011;117(1):125-33. **IF 5.997**
207. Relative decrease in the role played by hepatitis B virus infection in the aetiology of hepatocellular carcinoma during a 20-year period: a multicentre Italian study. Giannini EG, Savarino V, Risso D, Di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F,



- Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA.) group. *Liver Int.* 2011;31(2):192-6. **IF 4.116**
208. Interleukin 1 $\beta$  and tumor necrosis factor- $\alpha$  polymorphisms in autoimmune gastritis. Zorzetto V, Tollardo M, Plebani M, Zambon CF, Maddalo G, Farinati F. *Eur J Gastroenterol Hepatol.* 2011;23(2):196. **IF 1.968**
209. The war of the worlds: metaplastic versus nonmetaplastic atrophic gastritis. Rugge M, Fassan M, Farinati F, Genta RM. *Gastrointest Endosc.* 2011;73(2):411-2. **IF 6.501**
210. Rugge M, Fassan M, Pizzi M, Farinati F, Sturniolo GC, Plebani M, Graham DY. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. *World J Gastroenterol.* 2011;17(41):4596-601.
211. Farinati F, Giacomini A, Vanin V, Sergio A, Burra P, Cillo U, Di Nolfo A, Del Poggio P, Benvegna L, Zoli M, Borzio F, Giannini EG, Caturelli E, Cazzagon N, Rapaccini GL, Trevisani F; Italian Liver Cancer (ITA.LI.CA.) group. Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy. *Eur J Gastroenterol Hepatol.* 2012;24(2):195-202. **IF 1.968**
212. Zaninotto G, Parente P, Salvador R, Farinati F, Tieppo C, Passuello N, Zanatta L, Fassan M, Cavallin F, Costantini M, Mescoli C, Battaglia G, Ruol A, Ancona E, Rugge M. Long-term follow-up of Barrett's epithelium: medical versus antireflux surgical therapy. *J Gastrointest Surg.* 2012;16(1):7-14; discussion 14-5. **IF 2.963**
213. Farinati F, Giacomini A, Vanin V. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. *Cancer Chemother Pharmacol.* 2011;68(6):1639-40; author reply 1641-2. **IF 2.737**
214. Farinati F. Digestive oncology: It's now or never. *Dig Liver Dis.* 2012;44(2):180-1. **IF 3.061**
215. Vitale A, Navaglia F, Ramírez Morales R, Frigo AC, Basso D, D'Amico F, Zanus G, Bonsignore P, Farinati F, Burra P, Senzolo M, Grigoletto F, Plebani M, Cillo U. Molecular refinement of clinical staging in hepatocellular carcinoma patients evaluated for potentially curative therapies. *PLoS One.* 2011;6(9):e23093. **IF 2.806**
216. Giannini EG, Farinati F, Trevisani F. Alpha-fetoprotein in hepatocellular carcinoma surveillance: wake not the dead. *Hepatology.* 2011;54(1):376-7. **IF 13.246**
217. Stroffolini T, Trevisani F, Pinzello G, Brunello F, Tommasini MA, Iavarone M, Di Marco V, Farinati F, Del Poggio P, Borzio F, Borzio M, Caturelli E, Di Nolfo MA, Frigerio M, Brancaccio G, Gaeta GB. Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. *Dig Liver Dis.* 2011;43(11):875-80. **IF 3.061**
218. Vitale A, Morales RR, Zanus G, Farinati F, Burra P, Angeli P, Frigo AC, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegna L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F, Cillo U; Italian Liver Cancer group. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. *Lancet Oncol.* 2011;12(7):654-62. **IF 47.831**
219. Tieppo C, Betterle C, Basso D, Mescoli C, Rugge M, Martini C, Zorzetto V, Maddalo G, Cazzagon N, Nitti D, Farinati F. Gastric type I carcinoid: a pilot study with human G17DT immunogen vaccination. *Cancer Immunol Immunother.* 2011;60(7):1057-60. **IF 4.711**
220. Giacomini A, Cazzagon N, Sergio A, Vanin V, Farinati F. Hepatitis B virus-related hepatocellular carcinoma: primary, secondary, and tertiary prevention. *Eur J Cancer Prev.* 2011;20(5):381-8. **IF 2.556**

221. Rugge M, Fassan M, Pizzi M, Pennelli G, Nitti D, Farinati F. Operative Link for Gastritis Assessment gastritis staging incorporates intestinal metaplasia subtyping. *Hum Pathol.* 2011;42(10):1539-44. **IF 3.014**
222. Dei Tos AP, Laurino L, Bearzi I, Messerini L, Farinati F; Gruppo Italiano Patologi Apparato Digerente (GIPAD); Società Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology, Italian division (SIAPEC/IAP). Gastrointestinal stromal tumors: the histology report. *Dig Liver Dis.* 2011;43 Suppl 4:S304-9. **IF 3.061**
223. Santi V, Buccione D, Di Micoli A, Fatti G, Frigerio M, Farinati F, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Bernardi M, Trevisani F. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. *J Hepatol.* 2012;56(2):397-405. **IF 12.486**
224. Zerbi A, Capitanio V, Boninsegna L, Pasquali C, Rindi G, Delle Fave G, Del Chiaro M, Casadei R, Falconi M; AISP Network Study Group. Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases. *Langenbecks Arch Surg.* 2011;396(3):313-21. **IF 2.203**
225. Giannini EG, Farinati F, Del Poggio P, Rapaccini GL, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Ten-year outcome of radiofrequency thermal ablation for hepatocellular carcinoma: an Italian experience. *Am J Gastroenterol.* 2012;107(10):1588-9; author reply 1590. **IF 9.566**
226. Kotsafti A, Farinati F, Cardin R, Cillo U, Nitti D, Bortolami M. Autophagy and apoptosis-related genes in chronic liver disease and hepatocellular carcinoma. *BMC Gastroenterol.* 2012;12:118. **IF 2.212**
227. Zorzetto V, Maddalo G, Basso D, Farinati F. Immunotherapy for gastric premalignant lesions and cancer. *Immunotherapy.* 2012;4(6):587-99. **IF 2.716**
228. Giacomini A, Sergio A, Vanin V, Gazzola A, Cazzagon N, Farinati F. Molecular targeted therapy in hepatocellular carcinoma: present achievements and future challenges. *Dig Dis.* 2012;30(3):284-8. **IF 1.775**
229. Cardin R, Picocchi M, Sinigaglia A, Lavezzo E, Bortolami M, Kotsafti A, Cillo U, Zanus G, Mescoli C, Rugge M, Farinati F. Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma. *BMC Cancer.* 2012;12:177 Erratum in: *BMC Cancer.* 2014;14:284. multiple author names corrected. **IF 3.288**
230. Giannini EG, Marengo S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Anna Di Nolfo M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. *Hepatology.* 2012;56(4):1371-9 **IF 13.246**
231. Fassan M, Pizzi M, Farinati F, Nitti D, Zagonel V, Genta RM, Rugge M. Lesions indefinite for intraepithelial neoplasia and OLGA staging for gastric atrophy. *Am J Clin Pathol.* 2012;137(5):727-32. **IF 2.400**
232. Rugge M, Fassan M, Pizzi M, Zorzetto V, Maddalo G, Realdon S, De Bernard M, Betterle C, Cappellesso R, Pennelli G, de Boni M, Farinati F. Autoimmune gastritis: histology phenotype and OLGA staging. *Aliment Pharmacol Ther.* 2012;35(12):1460-6. **IF 7.286**

233. Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J; SHARP Investigators Study Group. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. *Clin Cancer Res.* 2012;18(8):2290-300. **IF 9.619**
234. Farinati F, Giacomini A, Vanin V, Giannini E, Trevisani F. TACE treatment in hepatocellular carcinoma: what should we do now? *J Hepatol.* 2012;57(1):221-2. **IF 12.486**
235. Cucchetti A, Trevisani F, Cescon M, Ercolani G, Farinati F, Poggio PD, Rapaccini G, Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Pinna AD; Italian Liver Cancer (ITA.LI.CA) Group. Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. *J Hepatol.* 2012;56(5):1089-96. **IF 12.486**
236. Negrini M, Miotto E, Sabbioni S, Cardin R, Rugge M, Tieppo C, Picocchi M, Maddalo G, Nitti D, Farinati F. MINT31 methylation in gastric noninvasive neoplasia: potential role in the secondary prevention of gastric cancer. *Eur J Cancer Prev.* 2012;21(5):442-8. **IF 2.556**
237. Zerbi A, Capitanio V, Boninsegna L, Delle Fave G, Pasquali C, Rindi G, Campana D, Falconi M; AISP-Network Study Group. Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. *HPB (Oxford).* 2013;15(12):935-43. **IF 3.29**
238. Floreani A, Farinati F. Risk factors associated with hepatocellular carcinoma in primary biliary cirrhosis. *Hepatology.* 2013;58(4):1520-1. **IF 13.246**
239. Cillo U, Vitale A, Dupuis D, Corso S, Neri D, D'Amico F, Gringeri E, Farinati F, Vincenzi V, Zanusi G. Laparoscopic ablation of hepatocellular carcinoma in cirrhotic patients unsuitable for liver resection or percutaneous treatment: a cohort study. *PLoS One.* 2013;8(2):e57249. **IF 2.806**
240. Borzio M, Fornari F, De Sio I, Andriulli A, Terracciano F, Parisi G, Francica G, Salvagnini M, Marignani M, Salmi A, Farinati F, Carella A, Pedicino C, Dionigi E, Fanigliulo L, Cazzaniga M, Ginanni B, Sacco R; EpaHCC Group. Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study. *Future Oncol.* 2013;9(2):283-94. **IF 2.131**
241. Scarpa R, Alaggio R, Norberto L, Furmaniak J, Chen S, Smith BR, Masiero S, Morlin L, Plebani M, De Luca F, Salerno MC, Giordano R, Radetti G, Ghizzoni L, Tonini G, Farinati F, Betterle C. Tryptophan hydroxylase autoantibodies as markers of a distinct autoimmune gastrointestinal component of autoimmune polyendocrine syndrome type 1. *J Clin Endocrinol Metab.* 2013;98(2):704-12. **IF 4.03**
242. Cardin R, Picocchi M, Martines D, Scribano L, Petracco M, Farinati F. Effects of coffee consumption in chronic hepatitis C: a randomized controlled trial. *Dig Liver Dis.* 2013;45(6):499-504. **IF 3.061**
243. Barrett's esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA). Rugge M, Zaninotto G, Parente P, Zanatta L, Cavallin F, Germanà B, Macrì E, Galliani E, Iuzzolino P, Ferrara F, Marin R, Nisi E, Iaderosa G, Deboni M, Bellumat A, Valiante F, Florea G, Della Libera D, Benini M, Bortesi L, Meggio A, Zorzi MG, Depretis G, Miori G, Morelli L, Cataudella G, d'Amore ES, Franceschetti I, Bozzola L, Paternello E, Antonini C, Di Mario F, Dal Bò N, Furlanetto A, Norberto L, Polese L, Iommarini S, Farinati F, Battaglia G, Diamantis G, Realdon S, Guido E, Mastropaolo G, Canova D, Guerini A, Franceschi M, Zirillo M. *Ann Surg.* 2012 Nov;256(5):788-94; discussion 794-5. Erratum in: *Ann Surg.* 2013 Mar;257(3):576. D'amore, Emanuele [corrected to d'Amore, Emanuele S G]. **IF 8.980**



244. Giannini EG, Marengo S, Bruzzone L, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F. Hepatocellular carcinoma in patients without cirrhosis in Italy. *Dig Liver Dis.* 2013;45(2):164-9. **IF 3.061**
245. Piciocchi M, Cardin R, Vitale A, Vanin V, Giacomini A, Pozzan C, Maddalo G, Cillo U, Guido M, Farinati F. Circulating free DNA in the progression of liver damage to hepatocellular carcinoma. *Hepatology Int.* 2013;7(4):1050-7. **IF 2.164**
246. Giannini EG, Farinati F, Trevisani F. Adequate interval for hepatocellular carcinoma surveillance. *Am J Gastroenterol.* 2013;108(7):1174. **IF 9.566**
247. Di Tommaso L, Sangiovanni A, Borzio M, Park YN, Farinati F, Roncalli M. Advanced precancerous lesions in the liver. *Best Pract Res Clin Gastroenterol.* 2013;27(2):269-84. **IF 3.99**
248. Farinati F, Cardin R, Piciocchi M. Coffee, chronic diseases and cancer. *Eur J Clin Nutr.* 2013;67(8):898. **IF 3.057**
249. Italian Association for the Study of the Liver (AISF); AISF Expert Panel; AISF Coordinating Committee, Bolondi L, Cillo U, Colombo M, Craxi A, Farinati F, Giannini EG, Golfieri R, Levrero M, Pinna AD, Piscaglia F, Raimondo G, Trevisani F, Bruno R, Caraceni P, Ciancio A, Coco B, Fraquelli M, Rendina M, Squadrito G, Toniutto P. Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. *Dig Liver Dis.* 2013;45(9):712-23. **IF 3.061**
250. Cazzagon N, Trevisani F, Maddalo G, Giacomini A, Vanin V, Pozzan C, Poggio PD, Rapaccini G, Nolfo AM, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Foschi FG, Cabibbo G, Felder M, Ciccarese F, Missale G, Baroni GS, Morisco F, Pecorelli A, Farinati F; Italian Liver Cancer (ITA.LI.CA) Group. Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres. *Liver Int.* 2013;33(9):1420-7. **IF 4.116**
251. Cardin R, Piciocchi M, Tieppo C, Maddalo G, Zaninotto G, Mescoli C, Rugge M, Farinati F. Oxidative DNA damage in Barrett mucosa: correlation with telomeric dysfunction and p53 mutation. *Ann Surg Oncol.* 2013;20 Suppl 3:S583-9. **IF 4.041**
252. Giannini EG, Savarino V, Farinati F, Ciccarese F, Rapaccini G, Marco MD, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. *Liver Int.* 2013;33(10):1594-600. **IF 4.116**
253. Fassan M, Pizzi M, Realdon S, Balistreri M, Guzzardo V, Zagonel V, Castoro C, Mastracci L, Farinati F, Nitti D, Zaninotto G, Rugge M. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. *Hum Pathol.* 2013;44(9):1804-10. **IF 3.014**
254. Castelli G, Burra P, Giacomini A, Vitale A, Senzolo M, Cillo U, Farinati F. Sorafenib use in the transplant setting. *Liver Transpl.* 2014;20(9):1021-8. **IF 3.910**
255. Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Ludovico Rapaccini G, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group. Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype. *Semin Oncol.* 2014;41(2):252-8. **IF 6.212**
256. Cillo U, Noaro G, Vitale A, Neri D, D'Amico F, Gringeri E, Farinati F, Vincenzi V, Vigo M, Zanusi G; HePaTIC Study Group. Laparoscopic microwave ablation in patients with

- hepatocellular carcinoma: a prospective cohort study. *HPB (Oxford)*. 2014;16(11):979-86. **IF 3.29**
257. Giannini EG, Sammito G, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. *Cancer*. 2014;120(14):2150-7. **IF 5.997**
258. Cucchetti A, Trevisani F, Pecorelli A, Erroi V, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Giannini EG, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Baroni GS, Virdone R, Bernardi M, Pinna AD; Italian Liver Cancer Group. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. *J Hepatol*. 2014;61(2):333-41. **IF 12.486**
259. Cardin R, Piciocchi M, Bortolami M, Kotsafti A, Barzon L, Lavezzo E, Sinigaglia A, Rodriguez-Castro KI, Rugge M, Farinati F. Oxidative damage in the progression of chronic liver disease to hepatocellular carcinoma: an intricate pathway. *World J Gastroenterol*. 2014;20(12):3078-86. **IF 3.365**
260. Pozzan C, Cardin R, Piciocchi M, Cazzagon N, Maddalo G, Vanin V, Giacomini A, Pontisso P, Cillo U, Farinati F. Diagnostic and prognostic role of SCCA-IgM serum levels in hepatocellular carcinoma (HCC). *J Gastroenterol Hepatol*. 2014;29(8):1637-44. **IF 3.452**
261. Cardin R, Piciocchi M, Farinati F. Letter: coffee and chronic liver damage. *Aliment Pharmacol Ther*. 2014;39(6):643. **IF 7.286**
262. Del Poggio P, Olmi S, Ciccarese F, Di Marco M, Rapaccini GL, Benvegnù L, Borzio F, Farinati F, Zoli M, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. *Clin Gastroenterol Hepatol*. 2014;12(11):1927-33. **IF 7.680**
263. Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer Group. Significance of platelet and AFP levels and liver function parameters for HCC size and survival. *Int J Biol Markers*. 2014;29(3):e215-23. **IF 1.457**
264. Maddalo G, Spolverato Y, Rugge M, Farinati F. Gastrin: from pathophysiology to cancer prevention and treatment. *Eur J Cancer Prev*. 2014;23(4):258-63. **IF 2.556**
265. Carr BI, Pancoska P, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Marco MD, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters. *Semin Oncol*. 2014;41(3):406-414. **IF 6.212**
266. Buscarini E, Conte D, Cannizzaro R, Bazzoli F, De Boni M, Delle Fave G, Farinati F, Ravelli P, Testoni PA, Lisiero M, Spolaore P; Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO), Italian Society of Endoscopy (SIED), Italian Society of Gastroenterology (SIGE). White paper of Italian Gastroenterology: delivery of services for digestive diseases in Italy: weaknesses and strengths. *Dig Liver Dis*. 2014;46(7):579-89. **IF 3.061**
267. Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F. Low alpha-fetoprotein HCC and the role of GGTP. *Int J Biol Markers*. 2014;29(4):e395-402. **IF 1.457**

268. Zagari RM, Romano M, Ojetti V, Stockbrugger R, Gullini S, Annibale B, Farinati F, Ierardi E, Maconi G, Rugge M, Calabrese C, Di Mario F, Lizza F, Pretolani S, Savio A, Gasbarrini G, Caselli M. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. *Dig Liver Dis.* 2015;47(11):903-12. **IF 3.061**
269. Vitale A, Farinati F, Burra P, Trevisani F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Missale G, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Chiaramonte M, Spolverato G, Cillo U; Italian Liver Cancer Group. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor. *Liver Transpl.* 2015;21(10):1250-8. doi: **IF 3.910**
270. Russo FP, Rodríguez-Castro K, Scribano L, Gottardo G, Vanin V, Farinati F. Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease. *World J Hepatol.* 2015;7(8):1097-104. **IF 1.206**
271. Vitale A, Burra P, Frigo AC, Trevisani F, Farinati F, Spolverato G, Volk M, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Cillo U; Italian Liver Cancer (ITA.LI.CA) group. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. *J Hepatol.* 2015;62(3):617-24. **IF 12.486**
272. Sacco R, Mismas V, Granito A, Musettini G, Masi G, Caparello C, Vivaldi C, Felder M, Bresci G, Fornaro L; Italian Liver Cancer (IT.LI.CA) group. Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database. *Int J Biol Markers.* 2015;30(1):e65-72. **IF 1.457**
273. Sinigaglia A, Lavezzo E, Trevisan M, Sanavia T, Di Camillo B, Peta E, Scarpa M, Castagliuolo I, Guido M, Sarcognato S, Cappellesso R, Fassina A, Cardin R, Farinati F, Palù G, Barzon L. Changes in microRNA expression during disease progression in patients with chronic viral hepatitis. *Liver Int.* 2015;35(4):1324-33. **IF 4.116**
274. Borzio M, Dionigi E, Rossini A, Toldi A, Francica G, Fornari F, Salmi A, Farinati F, Vicari S, Marignani M, Terracciano F, Ginanni B, Sacco R. Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an Italian in-field experience. *Dig Dis Sci.* 2015;60(5):1465-73. **IF 2.875**
275. Biselli M, Conti F, Gramenzi A, Frigerio M, Cucchetti A, Fatti G, D'Angelo M, Dall'Agata M, Giannini EG, Farinati F, Ciccarese F, Andreone P, Bernardi M, Trevisani F. A new approach to the use of  $\alpha$ -fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. *Br J Cancer.* 2015;112(1):69-76. **IF 6.176**
276. Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Benvegnù L, Caturelli E, Zoli M, Borzio F, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Prognosis of untreated hepatocellular carcinoma. *Hepatology.* 2015;61(1):184-90. **IF 13.246**
277. Farinati F, Vanin V, Giacomini A, Pozzan C, Cillo U, Vitale A, Di Nolfo AM, Del Poggio P, Benvegnù L, Rapaccini G, Zoli M, Borzio F, Giannini EG, Caturelli E, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. *Liver Int.* 2015;35(1):223-31. **IF 4.116**

278. Giannini EG, Moscatelli A, Pellegatta G, Vitale A, Farinati F, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Missale G, Foschi FG, Gasbarrini A, Baroni GS, Virdone R, Masotto A, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group; Italian Liver Cancer ITA LI CA Group. Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. *Am J Gastroenterol.* 2016;111(1):70-7. **IF 9.566**
279. Fassan M, Saraggi D, Balsamo L, Cascione L, Castoro C, Coati I, De Bernard M, Farinati F, Guzzardo V, Valeri N, Zambon CF, Rugge M. Let-7c down-regulation in Helicobacter pylori-related gastric carcinogenesis. *Oncotarget.* 2016;7(4):4915-24. **IF 5.168**
280. Bucci L, Garuti F, Camelli V, Lenzi B, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Maida M, Felder M, Morisco F, Gasbarrini A, Gemini S, Foschi FG, Missale G, Masotto A, Affronti A, Bernardi M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group; Italian Liver Cancer ITA LI CA Group. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. *Aliment Pharmacol Ther.* 2016;43(3):385-99. **IF 7.286**
281. Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, Bellentani S; HCC-NAFLD Italian Study Group. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. *Hepatology.* 2016;63(3):827-38. **IF 13.246**
282. Coati I, Fassan M, Farinati F, Graham DY, Genta RM, Rugge M. Autoimmune gastritis: Pathologist's viewpoint. *World J Gastroenterol.* 2015;21(42):12179-89. **IF 3.365**
283. Piciocchi M, Cardin R, Cillo U, Vitale A, Cappon A, Mescoli C, Guido M, Rugge M, Burra P, Floreani A, Farinati F. Differential timing of oxidative DNA damage and telomere shortening in hepatitis C and B virus-related liver carcinogenesis. *Transl Res.* 2016;168:122-33. **IF 4.652**
284. Saraggi D, Fassan M, Bornschein J, Farinati F, Realdon S, Valeri N, Rugge M. From Barrett metaplasia to esophageal adenocarcinoma: the molecular background. *Histol Histopathol.* 2016;31(1):25-32. **IF 2.025**
285. Campello E, Zanetto A, Spiezia L, Radu CM, Gavasso S, Ferrarese A, Farinati F, Senzolo M, Simioni P. Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis. *Thromb Res.* 2016;143:118-21. **IF 2.650**
286. Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, Frigo AC, Giacomini A, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Biasini E, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Masotto A, Trevisani F, Cillo U; ITA.LI.CA study group. Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. *PLoS Med.* 2016;13(4):e1002006. **IF 11.862**
287. Cucchetti A, Trevisani F, Bucci L, Ravaioli M, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Maida M, Felder M, Morisco F, Gasbarrini A, Gemini S, Foschi FG, Missale G, Masotto A, Affronti A, Bernardi M, Pinna AD; Italian Liver Cancer Group. Years of life that could be saved from prevention of hepatocellular carcinoma. *Aliment Pharmacol Ther.* 2016;43(7):814-24. **IF 7.286**
288. Murer F, Pozzan C, Peserico G, Farinati F. Capecitabine in advanced hepatocellular carcinoma. *Dig Liver Dis.* 2016;48(10):1260-1. **IF 3.061**

289. Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Masotto A, Trevisani F. A Liver Index and its Relationship to Indices of HCC Aggressiveness. *J Integr Oncol*. 2016 Oct;5(4). pii: 178. **IF 1.58**
290. Bucci L, Garuti F, Lenzi B, Pecorelli A, Farinati F, Giannini EG, Granito A, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cammà C, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. The evolutionary scenario of hepatocellular carcinoma in Italy: an update. *Liver Int*. 2017;37(2):259-270. **IF 4.116**
291. Zanetto A, Shalaby S, Vitale A, Mescoli C, Ferrarese A, Gambato M, Franceschet E, Germani G, Senzolo M, Romano A, Angeli P, Rugge M, Farinati F, Forton DM, Cillo U, Burra P, Russo FP. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. *Liver Transpl*. 2017;23(9):1103-1112. **IF 3.910**
292. Saraggi D, Galuppini F, Remo A, Urso EDL, Bacchin D, Salmaso R, Lanza C, Bao RQ, Fanelli GN, Guzzardo V, Luchini C, Scarpa M, Farinati F, Fassan M, Rugge M. PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions. *Histopathology*. 2017;71(3):470-474. **IF 3.523**
293. Cappellesso R, Luchini C, Veronese N, Lo Mele M, Rosa-Rizzotto E, Guido E, De Lazzari F, Pilati P, Farinati F, Realdon S, Solmi M, Fassan M, Rugge M. Tumor budding as a risk factor for nodal metastasis in pT1 colorectal cancers: a meta-analysis. *Hum Pathol*. 2017;65:62-70. **IF 3.014**
294. Fassan M, Saraggi D, Balsamo L, Realdon S, Scarpa M, Castoro C, Coati I, Salmaso R, Farinati F, Guzzardo V, Arcidiacono D, Munari G, Gasparini P, Veronese N, Luchini C, Valeri N, Rugge M. Early miR-223 Upregulation in Gastroesophageal Carcinogenesis. *Am J Clin Pathol*. 2017;147(3):301-308. **IF 2.400**
295. Borzio M, Dionigi E, Vitale A, Rossini A, Marignani M, Fornari F, Vicari S, De Sio I, Farinati F, Bertolini E, Oliveri F, Leandro G, Francica G, Mitra M, Omazzi B, Boccia S, Salmi A, Toldi A, Sacco R. Management and prognosis of hepatocellular carcinoma in the elderly: Results of an in-field multicenter cohort study. *Liver Int*. 2017;37(8):1184-1192. **IF 4.116**
296. Cabibbo G, Petta S, Barbara M, Attardo S, Bucci L, Farinati F, Giannini EG, Negrini G, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Virdone R, Marra F, Mega A, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Colecchia A, Persico M, Craxì A, Trevisani F, Cammà C; Italian Liver Cancer (ITA.LI.CA) group. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. *J Hepatol*. 2017;67(1):65-71. **IF 12.486**
297. Russo FP, Bruno S, Farinati F. HCV clearance by direct antiviral therapy and occurrence/recurrence of hepatocellular carcinoma: A "true-or-false game". *Dig Liver Dis*. 2017;49(4):321-325. **IF 3.061**
298. Zanetto A, Senzolo M, Vitale A, Cillo U, Radu C, Sartorello F, Spiezia L, Campello E, Rodriguez-Castro K, Ferrarese A, Farinati F, Burra P, Simioni P. Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. *Dig Liver Dis*. 2017;49(4):440-445. **IF 3.061**

299. Cabibbo G, Petta S, Barbara M, Missale G, Virdone R, Caturelli E, Piscaglia F, Morisco F, Colecchia A, Farinati F, Giannini E, Trevisani F, Craxì A, Colombo M, Cammà C; ITA.LI.CA study group. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. *Liver Int.* 2017;37(8):1157-1166. **IF 4.116**
300. Petta S, Cabibbo G, Barbara M, Attardo S, Bucci L, Farinati F, Giannini EG, Tovoli F, Ciccacese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Colecchia A, Persico M, Boccaccio V, Craxì A, Bruno S, Trevisani F, Cammà C; Italian Liver Cancer (ITA.LI.CA) Group. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. *Aliment Pharmacol Ther.* 2017;45(1):160-168. **IF 7.286**
301. Pecorelli A, Lenzi B, Gramenzi A, Garuti F, Farinati F, Giannini EG, Ciccacese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Morisco F, Gasbarrini A, Baroni GS, Foschi FG, Biasini E, Masotto A, Virdone R, Bernardi M, Trevisani F; Italian LiverCancer (ITA.LI.CA) group. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. *Liver Int.* 2017;37(3):423-433. **IF 4.116**
302. Galuppini F, Pennelli G, Loupakis F, Lanza C, Vianello L, Sacchi D, Mescoli C, Salmaso R, Agostini M, Lonardi S, Farinati F, Rugge M, Fassan M. BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling. *Histopathology.* 2017. **IF 3.523**
303. Schiavinato A, Zanetto A, Pantano G, Tosato F, Nabergoj M, Fogar P, Piva E, Gambato M, Franceschet E, Floreani A, Farinati F, Burra P, Russo FP, Plebani M. Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents. *J Viral Hepat.* 2017. **IF 4.122**
304. Maddalo G, Fassan M, Cardin R, Piciocchi M, Marafatto F, Rugge M, Zaninotto G, Pozzan C, Castoro C, Ruol A, Biasiolo A, Farinati F. Squamous Cellular Carcinoma Antigen Serum Determination as a Biomarker of Barrett Esophagus and Esophageal Cancer: A Phase III Study. *J Clin Gastroenterol.* 2017. **IF 3.328**